Genflow Biosciences plc
Genflow Biosciences plc, together with its subsidiaries, engages in the research and development of gene therapy targeting the upstream biology of aging in the United Kingdom and Belgium. The company operates as a pre-clinical biotechnology company that focuses on developing biological interventions aimed at tackling the effects of aging, slowing, and halting the aging process, as well as reducin… Read more
Genflow Biosciences plc (GENFF) - Net Assets
Latest net assets as of June 2025: $-303.00K USD
Based on the latest financial reports, Genflow Biosciences plc (GENFF) has net assets worth $-303.00K USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($468.38K) and total liabilities ($771.38K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-303.00K |
| % of Total Assets | -64.69% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 2038.2 |
Genflow Biosciences plc - Net Assets Trend (2021–2024)
This chart illustrates how Genflow Biosciences plc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Genflow Biosciences plc (2021–2024)
The table below shows the annual net assets of Genflow Biosciences plc from 2021 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-403.01K | -180.65% |
| 2023-12-31 | $499.69K | -78.88% |
| 2022-12-31 | $2.37 Million | +4193.00% |
| 2021-12-31 | $55.12K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Genflow Biosciences plc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 478290500.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $5.19 Million | % |
| Total Equity | $-403.01K | 100.00% |
Genflow Biosciences plc Competitors by Market Cap
The table below lists competitors of Genflow Biosciences plc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Anmol India Limited
NSE:ANMOL
|
$3.48 Million |
|
WINMARK
BE:GBZ
|
$3.48 Million |
|
Sunrise Real Estate Group Inc
PINK:SRRE
|
$3.49 Million |
|
AI Unlimited Group, Inc.
OTCQB:AIUG
|
$3.49 Million |
|
EDM Resources Inc
PINK:SWNLF
|
$3.48 Million |
|
LABEL VIE
BC:LABEL-VIE
|
$3.48 Million |
|
Kiang Huat Sea Gull Trading Frozen Food Public Company Limited
BK:CHOTI
|
$3.48 Million |
|
International Network System PCL
BK:ITNS
|
$3.47 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Genflow Biosciences plc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 499,693 to -403,008, a change of -902,701 (-180.7%).
- Net loss of 1,587,235 reduced equity.
- New share issuances of 656,635 increased equity.
- Other factors increased equity by 27,899.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-1.59 Million | -393.85% |
| Share Issuances | $656.63K | +162.93% |
| Other Changes | $27.90K | +6.92% |
| Total Change | $- | -180.65% |
Book Value vs Market Value Analysis
This analysis compares Genflow Biosciences plc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | $0.00 | $0.01 | x |
| 2022-12-31 | $0.01 | $0.01 | x |
| 2023-12-31 | $0.00 | $0.01 | x |
| 2024-12-31 | $0.00 | $0.01 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Genflow Biosciences plc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-555.35%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -1792.68% | 0.00% | 0.00x | 5.02x | $-993.71K |
| 2022 | -56.43% | 0.00% | 0.00x | 1.11x | $-1.57 Million |
| 2023 | -372.30% | 0.00% | 0.00x | 2.14x | $-1.91 Million |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.55 Million |
Industry Comparison
This section compares Genflow Biosciences plc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Genflow Biosciences plc (GENFF) | $-303.00K | -1792.68% | N/A | $3.48 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |